Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK
14 March 2017
A new OHE report compares the availability and access of orphan medicinal products (OMPs) in the UK, France, Germany, Italy and Spain.
New Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
7 March 2017
Just published is a new report entitled: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. The publication is a report of the…
Value and Cancer: Journal of Cancer Policy Special Issue
25 January 2017
A special issue of the Journal of Cancer Policy entitled ‘Value and Cancer’ includes three papers authored by OHE researchers.
OHE Lunchtime Seminar with Andrea Manca: Economic Evaluation for Decision-making and the Value of Access to Individual Patient Data
16 January 2017
Professor Andrea Manca from the University of York will lead an OHE Lunchtime Seminar on 13th February 2017 on the topic of economic evaluation for decision-making…
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
1 December 2017
The centralised procedure was created in 1995 to facilitate access to innovative medicines across the European Union. Since then the scope of authorisation via the centralised…
Data Governance Arrangements for Real-World Evidence: South Korea
1 September 2017
In 2015, OHE published a report which set out the core principles that should govern how Real-World Data (RWD) is accessed or generated, and used credibly to generate Real-World Evidence (RWE), thereby working toward a set of “international standards”1.
New Publication: Assessing Evidence and Access Associated with NICE HTA Decisions Categorised as “Recommended in Line with Clinical Practice”
6 January 2017
A new OHE Research Paper assesses the nature of evidence used to reach HTA decisions which NICE have classified as “Recommended in Line with Clinical Practice”…
Incentives for New Drugs to Tackle Anti-Microbial Resistance
1 May 2017
Resistance to antibiotics is growing, posing a major health risk in rich and poor countries. Additional ways of rewarding R&D are required. Mechanisms designed to encourage…
Recently Published: Reports on Policy Options for Formulary Development in Middle-income Countries and A Case Study from Mexico
4 January 2017
OHE has published a new report discussing a framework to help middle-income countries efficiently identify medicines for formulary inclusion. A second publication applies this framework to…